Drug developed at Duke is approved by FDA as only therapy for congenital athymia

The phone rang into the pediatric unit that Louise Markert, M.D., Ph.D., was staffing as a junior faculty member in 1991. Had she not answered, there would have been little hope for the more than one hundred patients who were subsequently treated.

Related Keywords

Tennessee ,United States ,North Carolina ,Paul Martin ,Jie Li ,Betty Mccarthy ,Emily Henderson ,Barton Haynes ,Louise Markert ,Zelene Turner ,John Sleasman ,Stephanie Gupton ,Pediatric Division Of Allergy Immunology ,Department Of Pediatrics ,Division Of Pediatric ,Digeorge Syndrome ,Enzyvant Therapeutics ,Pediatric Transplant ,Cellular Therapy ,Pediatric Division ,Allergy Immunology ,Research ,Calcium ,Children ,Doctor ,Gene ,Gene Therapy ,Heart ,Heart Defect ,Mmunology ,Mh ,Yndrome ,Thymus ,